It says such tools could help companies screen new product ideas.
Fluxome (Easton, PA) is taking part in a project to develop software that may help quicken the development time for products such as nutraceuticals. Although the company declined to provide specific details, it says that the three-year, €2.9 million BioPreDyn project is being funded by the European Commission and its Seventh Framework Program, which supports R&D efforts in the EU.
In an interview with Nutritional Outlook, Jean-Marie Mouillon, Fluxome’s R&D director, explained that project will focus on developing analysis software for use earlier on in the development process. It says such tools could help companies screen new-product ideas and optimize the production process in a “reliable, predictive, and quantitative way.”
“We hope that by using [a] more in silico [computer-simulated] modeling approach at an early stage of product development, we will be able to improve our screening capacity for new products [and] also be able to better estimate the timeframe of the development phase of a product,” said Mouillon. However, he added, “It is too early to explain how the software [will] work…”
Fluxome says it is the only nutraceutical company participating in the project. Eight academic labs and three industrial companies, all from Europe, are participating. As for the software’s end-users, Fluxome says they may be both research institutions and private biotechnology companies like Fluxome.